• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Biogen (BIIB)

Common Shares
Sell: $116.86|Buy: $121.89|Change: 0.91 (0.76%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Address

225 Binney Street
Cambridge
MA
USA
02142

Telephone

+1 781 4642442

Website

https://www.biogen.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Biogen Inc First Quarter Earnings Conference Call for 20262026-05-01T08:30:00
Biogen Inc First Quarter Earnings Results for 20262026-05-01T00:00:00
Biogen Inc Fourth Quarter Earnings Conference Call for 20252026-02-12T08:30:00
Biogen Inc Fourth Quarter Earnings Results for 20252026-02-12T00:00:00
Biogen Inc Annual Report for 20252026-02-12T00:00:00
Biogen Inc Third Quarter Earnings Conference Call for 20252025-10-30T08:30:00
Biogen Inc Third Quarter Earnings Results for 20252025-10-30T00:00:00
Biogen Inc Second Quarter Earnings Conference Call for 20252025-08-01T08:30:00
Biogen Inc Second Quarter Earnings Results for 20252025-08-01T00:00:00
Biogen Inc Annual General Meeting for 20252025-06-20T09:00:00
Biogen Inc First Quarter Earnings Conference Call for 20252025-05-01T08:30:00
Biogen Inc First Quarter Earnings Result for 20252025-05-01T00:00:00

Previous key dates

NameKey Date
Biogen Inc First Quarter Earnings Conference Call for 20252025-05-01T08:30:00
Biogen Inc First Quarter Earnings Result for 20252025-05-01T00:00:00
TD Cowen 45th Annual Health Care Conference2025-03-03T09:10:00
Biogen Inc Fourth Quarter Earnings Conference Call for 20242025-02-12T08:30:00
Biogen Inc Fourth Quarter Earnings Result for 20242025-02-12T00:00:00
Biogen Inc Annual Report for 20242025-02-12T00:00:00
J.P. Morgan 43rd Annual Healthcare Conference2025-01-14T12:45:00
Biogen at the 7th Annual Evercore HealthCONx Conference2024-12-03T09:10:00
Biogen Inc Third Quarter Earnings Conference Call for 20242024-10-30T08:30:00
Biogen Inc Third Quarter Earnings Result for 20242024-10-30T00:00:00
Biogen at the Cantor Fitzgerald Global Healthcare Conference2024-09-18T13:20:00
Biogen at the Morgan Stanley 22nd Annual Global Healthcare Conference2024-09-04T10:00:00
Biogen Inc Second Quarter Earnings Conference Call for 20242024-08-01T08:30:00
Biogen Inc Second Quarter Earnings Result for 20242024-08-01T00:00:00
Biogen Inc Annual General Meeting for 20242024-06-20T09:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2025 AJ Bell. All rights reserved.